Venlafaxine Hydrochloride
"Venlafaxine Hydrochloride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclohexanol and phenylethylamine derivative that functions as a SEROTONIN AND NORADRENALINE REUPTAKE INHIBITOR (SNRI) and is used as an ANTIDEPRESSIVE AGENT.
Descriptor ID |
D000069470
|
MeSH Number(s) |
D02.033.415.510.500.901 D02.092.471.683.948 D02.455.426.392.368.367.318.750 D10.289.510.500.901
|
Concept/Terms |
Venlafaxine Hydrochloride- Venlafaxine Hydrochloride
- Hydrochloride, Venlafaxine
- Cyclohexanol, 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)-, hydrochloride
- 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)cyclohexanol HCl
Wy 45030- Wy 45030
- Wy-45030
- Wy45030
- Wy-45,030
- Wy 45,030
- Wy45,030
Effexor- Effexor
- Trevilor
- Vandral
- Efexor
|
Below are MeSH descriptors whose meaning is more general than "Venlafaxine Hydrochloride".
Below are MeSH descriptors whose meaning is more specific than "Venlafaxine Hydrochloride".
This graph shows the total number of publications written about "Venlafaxine Hydrochloride" by people in this website by year, and whether "Venlafaxine Hydrochloride" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2002 | 0 | 2 | 2 |
2003 | 0 | 1 | 1 |
2004 | 0 | 1 | 1 |
2005 | 0 | 2 | 2 |
2006 | 0 | 1 | 1 |
2008 | 0 | 1 | 1 |
2013 | 0 | 1 | 1 |
2014 | 0 | 1 | 1 |
2017 | 0 | 1 | 1 |
2018 | 0 | 1 | 1 |
2020 | 1 | 0 | 1 |
2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Venlafaxine Hydrochloride" by people in Profiles.
-
Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial. Mol Psychiatry. 2024 Aug; 29(8):2287-2295.
-
Multinational Investigation of Fracture Risk with Antidepressant Use by Class, Drug, and Indication. J Am Geriatr Soc. 2020 07; 68(7):1494-1503.
-
Effect of Problem-Solving Therapy Versus Supportive Management in Older Adults with Low Back Pain and Depression While on Antidepressant Pharmacotherapy. Am J Geriatr Psychiatry. 2018 07; 26(7):765-777.
-
Association of QT-Prolonging Medication Use in CKD with Electrocardiographic Manifestations. Clin J Am Soc Nephrol. 2017 09 07; 12(9):1409-1417.
-
Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review. Support Care Cancer. 2015 Feb; 23(2):513-24.
-
The effects of venlafaxine and cognitive behavioral therapy alone and combined in the treatment of co-morbid alcohol use-anxiety disorders. Behav Res Ther. 2013 Nov; 51(11):729-35.
-
The SNRI venlafaxine improves emotional unawareness in patients with post-stroke depression. Hum Psychopharmacol. 2009 Jun; 24(4):331-6.
-
Differences between daily smokers, chippers, and nonsmokers with co-occurring anxiety and alcohol-use disorders. Addict Behav. 2008 Nov; 33(11):1425-1431.
-
The DRD2 TaqI-B polymorphism and its relationship to smoking abstinence and withdrawal symptoms. Pharmacogenomics J. 2007 Aug; 7(4):266-74.
-
Combined effects of venlafaxine, nicotine replacement, and brief counseling on smoking cessation. Exp Clin Psychopharmacol. 2005 Nov; 13(4):282-92.